Wat is de prijs voor AbbVie Inc. (ABBV)

Het prijs van AbbVie Inc. (ABBV) is $207.15

Wat is de marktkapitalisatie voor AbbVie Inc. (ABBV)

Marktkapitalisatie voorAbbVie Inc. (ABBV) is $366.28B

AbbVie Inc. (ABBV) Prijsgeschiedenis

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Jaar	Prestaties
2026 (TTM)	-7.43%
2025	28.51%
2024	16.39%
2023	-7.17%
2022	27.60%
2021	21.67%
2020	19.07%
2019	0.53%
2018	-9.28%
2017	57.12%
2016	7.67%
2015	-15.03%
2014	29.37%
2013	0.00%

Jaar

Prestaties

2026 (TTM)

-7.43%

2025

28.51%

2024

16.39%

2023

-7.17%

2022

27.60%

2021

21.67%

2020

19.07%

2019

0.53%

2018

-9.28%

2017

57.12%

2016

7.67%

2015

-15.03%

2014

29.37%

2013

0.00%

Bedrijf	Aandelenkoers	Verandering 1jr%	Land
Eli Lilly LLY.US	$916.42	10.84%	US
AstraZeneca PLC AZN.US	$187.14	157.34%	GB
Johnson & Johnson JNJ.US	$239.93	48.36%	US
Novartis AG NVS.US	$150.75	36.87%	CH
Merck & Co., Inc. MRK.US	$119.37	35.48%	US

Bedrijf

Aandelenkoers

Verandering 1jr%

Land